LCTX

0.5901

14.58% 0.0751

Dopo l'orario di chiusura: .60 0.0099 +1.68%

Lineage Cell Therapeutics Inc (LCTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.515

Aprire:

$0.535

Volume 24 ore:

5.57M

Relative Volume:

2.79

Capitalizzazione di mercato:

$130.07M

Reddito:

$8.95M

Utile/perdita netta:

$-21.49M

Rapporto P/E:

-4.9175

EPS:

-0.12

Flusso di cassa netto:

$-29.24M

1 W Prestazione:

+18.73%

1M Prestazione:

+7.92%

6M Prestazione:

-35.75%

1 anno Prestazione:

-51.23%

Intervallo 1D:

$0.50

$0.5901

Intervallo di 1 settimana:

$0.481

$0.5901

Portata 52W:

$0.481

$1.61

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Nome

Lineage Cell Therapeutics Inc

Settore

Healthcare (1174)

Industria

Biotechnology (669)

Telefono

510-871-4188

Indirizzo

2173 Salk Avenue, Suite 200, Carlsbad, CA

Dipendente

Cinguettio

@LineageCell

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

LCTX's Discussions on Twitter

Confronta LCTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LCTX Lineage Cell Therapeutics Inc	0.5901	130.07M	8.95M	-21.49M	-29.24M	-0.12
VRTX Vertex Pharmaceuticals Inc	407.11	104.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	718.15	78.92B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	621.29	37.15B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	234.28	30.22B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.79	27.76B	3.30B	-501.07M	1.03B	-2.1146

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-08-20	Iniziato	Craig Hallum	Buy
2022-11-02	Iniziato	Robert W. Baird	Outperform
2022-06-14	Iniziato	B. Riley Securities	Buy
2021-08-19	Iniziato	Noble Capital Markets	Outperform
2021-03-31	Iniziato	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie

08:10 AM

Lineage Cell price target lowered to $2 from $3 at D. Boral Capital - Yahoo Finance

08:10 AM

02:43 AM

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World

02:43 AM

Jan 03, 2025

The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts - Benzinga

Jan 03, 2025

D. Boral Capital Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat

Jan 03, 2025

Jan 01, 2025

State Street Corp Acquires 45,483 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World

Jan 01, 2025

Dec 30, 2024

Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register

Dec 30, 2024

Dec 28, 2024

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1%Here's What Happened - MarketBeat

Dec 28, 2024

Dec 17, 2024

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround - Yahoo Finance

Dec 17, 2024

Dec 14, 2024

BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 - Marketscreener.com

Dec 14, 2024

Dec 13, 2024

HC Wainwright Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World

Dec 05, 2024

Stem cell therapy companies take different roads to reproducibility - BioCentury

Dec 05, 2024

Dec 04, 2024

Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com

Dec 04, 2024

Dec 03, 2024

Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio? - Yahoo Finance

Dec 03, 2024

Dec 01, 2024

Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner’s Portfolio? - Insider Monkey

Dec 01, 2024

Nov 26, 2024

Lineage Cell Therapeutics CFO Jill Howe buys $8,850 in stock - Investing.com

Nov 26, 2024

Lineage Cell Therapeutics CFO Jill Howe buys $8,850 in stock By Investing.com - Investing.com Australia

Nov 26, 2024

Lineage Cell Therapeutics director buys $22,639 in common shares - Investing.com India

Nov 26, 2024

Nov 25, 2024

Lineage Cell Therapeutics director buys $22,639 in common shares By Investing.com - Investing.com Australia

Nov 25, 2024

Nov 23, 2024

Brian M. Culley Buys 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock - MarketBeat

Nov 23, 2024

Nov 21, 2024

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering - Business Wire

Nov 21, 2024

Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Nov 21, 2024

Lineage Cell Therapeutics FY2024 EPS Boosted by Cantor Fitzgerald - MarketBeat

Nov 21, 2024

Lineage Cell Therapeutics secures $30 million in direct offering By Investing.com - Investing.com Australia

Nov 21, 2024

LCTX Stock Touches 52-Week Low at $0.73 Amid Market Challenges - Investing.com Australia

Nov 21, 2024

Nov 20, 2024

Lineage Cell Therapeutics tumbles after pricing $66M securities offering - MSN

Nov 20, 2024

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering - BioSpace

Nov 20, 2024

Lineage Cell Therapeutics secures $30 million in direct offering - Investing.com

Nov 20, 2024

Lineage Cell Therapeutics Launches $66M Direct Offering with Warrants for OpRegen Development | LCTX Stock News - StockTitan

Nov 20, 2024

Allogeneic Stem Cells Market Is Expected To Reach $2.0 Billion - openPR

Nov 20, 2024

Nov 19, 2024

D. Boral Capital Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy Recommendation - MSN

Nov 19, 2024

Nov 18, 2024

Boral Capital sets Buy rating for Lineage Cell stock - Investing.com

Nov 18, 2024

Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital - TipRanks

Nov 18, 2024

Nov 15, 2024